Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study
Melek Simsek(Vrije Universiteit Amsterdam), Nanne K.H. de Boer, Adriaan A. van Bodegraven(Zuyderland Medisch Centrum), F. Schepers(Teva Pharmaceuticals (Netherlands)), Else van de Poel(Teva Pharmaceuticals (Netherlands)), Frank Hoentjen(Radboud University Nijmegen), P van Boeckel(St. Antonius Ziekenhuis), Maarten A.C. Meijssen(Isala), Gerard Dijkstra(University Medical Center Groningen), Chris J. Mulder(Amsterdam University Medical Centers), Bindia Jharap(Meander Medisch Centrum), Ana Petrak(Teva Pharmaceuticals (Netherlands)), Paul J. Boekema(Radboud University Nijmegen), Marleen de Leest(Rijnstate Hospital), Sigal Kaplan(Teva Pharmaceuticals (Israel)), Herma H. Fidder(University Medical Center Utrecht), Ingrid Gisbertz(Ziekenhuis Bernhoven), F J G M Kubben(Maasstad Ziekenhuis), Maurice G. Rüssel(Medisch Spectrum Twente), Dirk van Asseldonk(Noordwest Ziekenhuisgroep)
Cited by 12
Related Papers
European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten‐related disorders
|United European Gastroenterology Journal|2019|987
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
|Clinical and Translational Gastroenterology|2016|724